Premium
Lixisenatide (Lyxumia): new GLP‐1 mimetic for type 2 diabetes
Author(s) -
Chaplin Steve
Publication year - 2014
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1177
Subject(s) - lixisenatide , medicine , type 2 diabetes , adverse effect , diabetes mellitus , pharmacology , endocrinology , exenatide
Abstract Lixisenatide is a new GLP‐1 mimetic for use in type 2 diabetes with oral agents and/or insulin. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Dr Frank Joseph discusses its place in therapy.